Filing Flows › Agios Pharmaceuticals (AGIO) › Q4 2025
Agios Pharmaceuticals (AGIO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 12, 2026
Agios Pharmaceuticals (AGIO) reported revenue of $20.0M for the fourth quarter 2025 (Q4 2025), +86% from a year earlier and +55% from the quarter before. Operating margin was -608.9%, net loss $108M (541.1% of revenue).
Agios Pharmaceuticals, Q4 2025: revenue $20.0M (+86% year over year), operating margin -608.9%, net loss $108M, operating cash flow −$96.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.0M | +55% | +86% |
| Operating profit | −$122M | — | — |
| Net earnings | −$108M | — | — |
| Operating cash flow | −$96.2M | — | — |
What changed
Revenue was $20.0M in Q4 2025, up 86% year over year and up 55% from the previous quarter.
Operating costs exceeded revenue by $121.6M, an operating margin of -608.9%. Total costs grew 4% against revenue growth of 86%. The fastest-growing cost line was Cost of revenue (+49%). The quarter ended with a net loss of $108.0M, wider than the previous quarter's $103.4M loss.
Operating cash flow was −$96.2M. Non-cash charges added back $14.1M of share-based compensation. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$97.3M.
Questions
What was Agios Pharmaceuticals' revenue in the fourth quarter 2025?
Agios Pharmaceuticals (AGIO) reported revenue of $20.0M for the fourth quarter 2025 (Q4 2025), +86% from a year earlier and +55% from the quarter before.
Was Agios Pharmaceuticals profitable in the fourth quarter 2025?
Operating loss was $122M (-608.9% of revenue) and net loss $108M.